Everolimus
- OralEverolimusCerticanHalf-life ~30 hours
Mechanism of Action
- Forms a complex with FKBP-12 to inhibit mTOR, a key regulatory protein, and induces cell cycle arrest of T cells, B cells and other non-immune cells.
Clinical Use
- Indications
- Prevention of graft rejection following kidney, liver or heart transplantation
- Adverse Effects
- Pancytopaenia
- Infections (particularly respiratory and urinary tract)
- Poor wound healing
- Mouth ulcers
- Male hypogonadism
- Dyslipidaemia
- Insomnia
- Anxiety
- Headache